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Abstract
Purpose Patients with advanced GIST following standard
imatinib and sunitinib often have good performance status
and need additional therapy. This study tested nilotinib, a
second-generation tyrosine kinase inhibitor, in patients with
advanced GIST refractory to standard therapies.
Methods This single-center open-label phase II study has
a primary objective to determine progression-free survival
at 6 months. Using a novel statistical design, 17 patients
were to be enrolled; if ¸10 were progression free (PF) at
2 months, 19 additional patients would be enrolled. The
therapy was considered of beneWt if ¸13 of 36 patients
were PF at 6 months. All patients signed informed consent
and entry criteria included normal cardiac function. Explor-
atory analyses correlating genotype with response were
also performed.
Results Thirteen patients were treated; 2 had received
agents after imatinib and sunitinib. Treatment was well
tolerated with one grade 4 anemia attributed to nilotinib.
No measurable responses were observed; median time to
progression was 2 months. One patient remained on study
with stable disease for 12 months. Mutation testing is avail-
able from 10 primary tumors with 7 exon 11 mutations, 1
exon 9 mutation, and 2 without KIT/PDGFR mutations.
Two samples from recurrent disease had 2 mutations, both
primary exon 11 mutations with an additional exon 17
mutation, including the patient with prolonged stable
disease.
Conclusions Nilotinib was well tolerated in these patients
with advanced GIST. Accrual was halted due to insuYcient
clinical beneWt. However, nilotinib may provide beneWt to
speciWc subsets of advanced GIST with exon 17 mutations.
Keywords GIST · Tyrosine kinase inhibitor · Nilotinib · 
Kit mutations · Secondary mutations
Introduction
Imatinib, a selective inhibitor of several tyrosine kinases,
including ABL, ARG, KIT, and PDGFRA/B, has signiW-
cantly improved the clinical outcome of patients with
advanced GIST. Treatment with imatinib may be of clinical
beneWt of 80–90% of patients with advanced or metastatic
GIST, with a median time to progression of 2 years [1, 2].
Sunitinib, an oral multitargeted tyrosine kinase inhibitor
with activity against KIT, PDGFR, VEGFR, and FLT-
1/KDR, is utilized in the second-line setting. A phase III [3]
double-blind placebo-controlled trial testing sunitinib
showed that the time to progression was signiWcantly
longer in the sunitinib group than in the placebo group (6.3
vs. 1.5 months). However, despite initial response or stabil-
ization of the disease, secondary resistance develops in
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most patients after approximately 7 months. Patients
progressing following standard imatinib and sunitinib
often still have good performance status and need addi-
tional therapy.
This study was undertaken to evaluate the beneWt of nil-
otinib, a second-generation tyrosine kinase inhibitor that
functions via ATP-competitive inhibition. Nilotinib was
developed to optimize binding to bcr-abl for the therapy of
chronic myelogenous leukemia. In vitro, it can inhibit KIT
and PDGFR phosphorylation, has clinical activity against
imatinib-resistant cell lines, and achieves higher intracellu-
lar concentrations compared to imatinib. Data from a phase
I study [4] suggest that nilotinib is well tolerated and has
clinical activity in patients with imatinib-resistant GIST
who have failed second-line targeted therapies.
Patients and methods
Study objectives and design
This was a single-center open-label phase II study. The pri-
mary endpoint was to establish the progression-free sur-
vival (PFS) rate at 6 months in patients receiving nilotinib,
who had been previously treated with at least imatinib and
sunitinib. The secondary endpoint was to determine the
response rate to nilotinib. An exploratory endpoint correlat-
ing genotype with response was also performed.
Patients with pathologically conWrmed advanced GIST
were eligible for this study if they met the following key
criteria: age ¸18 years, failure of treatment with imatinib
and sunitinib, measurable disease to RECIST criteria [12],
an ECOG performance status (PS) of 0–2, a life expectancy
of greater than 12 weeks, and adequate major organ func-
tion. Key exclusion criteria included abnormal cardiac
function, chronic liver disease, and other severe and/or
uncontrolled concurrent medical diseases. The study was
approved by the Institutional Review Board of Fox Chase
Cancer Center, and written informed consent was obtained
from all patients.
Nilotinib was administered orally (fasting) at a dose of
400 mg BID, every 12 h continuously. All patients were
scheduled to continue treatment until disease progression or
unacceptable toxicity. Patients had regular physical exami-
nation, evaluation of performance status, complete blood
count, serum chemistry, and assessment of toxic eVects and
tumor response. Tumor evaluation was performed at base-
line and every 8 weeks thereafter by CT scan of chest,
abdomen, and pelvis or MRI of abdomen and pelvis, and
CT scan of chest. Objective tumor response was deWned
according to RECIST [5]. In this study, the objective tumor
response was also evaluated utilizing CHOI criteria [6] as
well, to obtain data on the role of CHOI criteria to assess
disease response in patient with advanced GIST refractory
to imatinib and sunitinib.
Progression-free survival, the primary endpoint, was
deWned as the duration of time from start of the treatment to
time of progression or death, according to RECIST criteria.
Toxicity was graded according to the National Cancer Insti-
tute Common Toxicity Criteria (CTCAE Version 3.0).
Molecular testing at Fox Chase Cancer Center for the
determination of KIT and PDGFRA mutations was per-
formed if tumor samples from the primary tumor resection
were available. Blood samples were collected from all
patients at baseline and at the time of the Wrst tumor assess-
ment for potential further study.
Statistical design
The study tested the composite null hypothesis that the
chance of PFS to 2 months is at most 60% and the chance of
PFS to 6 months is at most 25% utilizing a new phase II
design that allows evaluation for futility both early in patient
numbers and early in the course of treatment [7]. An initial
17 patients were to be entered; if at least 11/17 were PF at
2 months, an additional 19 patients were to be added.
Patients from the initial cohort who are PFS at 2 months con-
tinue on study while PF and are followed for 6 months as are
the 19 new patients. If the number of PF patients from both
initial and second cohorts at 6 months is at least 13/36, we
will reject the null hypothesis. The study has 90.4% overall
power and 3.4% overall type I error. The chance of stopping
the study early in a treatment arm is 55% under the null
hypothesis. The chance of stopping early in error in any treat-
ment arm (when the chances are 80% and 50% for 2 month
and 6 month PFS, respectively) is 4%. Therefore, for the
standard phase II design, up to 36 patients will be accrued.
Results
Patients
Between July 2008 and July 2009, 15 patients were signed
consent for this study. Two patients were judged to be ineli-
gible: One patient due to a cardiac arrhythmia identiWed dur-
ing screening. A second patient with a history of GIST
diagnosed at another institution began therapy having previ-
ously received imatinib and sunitinib with evidence of
response; pathology review diagnosed a malignant Wbrous
tumor, and mutational testing identiWed no KIT or PDGFRA
mutations. Thirteen patients were treated as per protocol and
are evaluable for response and toxicity evaluation. Charac-
teristics of the patients are summarized in Table 1. The
median age was 63 years (range 54–78), and the median
ECOG performance status was 1 (range 0–1). PrimaryCancer Chemother Pharmacol (2012) 69:977–982 979
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tumor site was stomach (n = 6), small bowel (n =5 ) ,  a n d
colon/rectum (n = 2), while the most common metastatic
sites were liver and peritoneum. All patients had received
prior imatinib and sunitinib; two patients had received prior
medical therapy beyond imatinib and sunitinib.
Tolerability
Treatment was generally well tolerated. Side eVects attrib-
uted to nilotinib are listed in Table 2. The most common
adverse events included fatigue (100%), anorexia (61%),
constipation (54%), anemia (92%), and leucopenia (54%).
Additional side eVects included were GI related: diarrhea
(38%), nausea (38%), abdominal pain (38%); dyspnea
(38%), elevated alkaline phosphatase (46%), hypoalbumi-
nemia (46%), and electrolyte abnormalities: hyperkalemia
(38%), hyponatremia (30%), and hypomagnesemia (30%).
Most of these adverse events were mild or moderate (grade
1 or 2). Side eVects of grade 3 occurred in 23% of patients.
One patient had a grade 4 anemia. The median exposure to
nilotinib was 42.5 days (range 21.5–372).
Dose modiWcations
Dose modiWcations were utilized for management of toxici-
ties as speciWed in the protocol. Five patients (42%)
required drug to be held. One patient (8%) required a dose
reduction for a rise in creatinine that occurred in the setting
of hospitalization for pneumonia. After 8 weeks at 400 mg
daily, the dose was escalated back to 400 mg BID as the
creatinine returned to baseline where it remained. The over-
all dose density was 93.4%, with seven patients (58%) tak-
ing all prescribed doses.
EYcacy
Accrual was halted after 13 eligible patients enrolled due to
insuYcient clinical beneWt, since 8 of 13 patients pro-
gressed by 2 months. Assessment of response was made
utilizing both RECIST and CHOI criteria. Data on antitu-
mor response are shown in Table 3. Of the thirteen patients
entered on study, 12 had follow-up imaging to assess
response. There were no complete or partial responses by
RECIST, with 4 patients achieving stable disease, one of
which lasted 12 months.
Disease assessment by CHOI
Eight of the 12 patients were able to have response deter-
mined by CHOI criteria. One patient had stable disease by
both criteria, one patient progressive disease by RECIST
and stable disease by CHOI, a third patient had stable dis-
ease by RECIST and response by CHOI, and the remaining
5 patients all had progressive disease by both criteria (see
Table 3). Of note, the patient with the response by CHOI
was taken oV study for clinical progression.
Molecular testing results
Of 10 patients who underwent molecular testing of primary
tumor samples, KIT exon 11 and 9 mutations were observed
in Wve and one patients, respectively. The results are summa-
rized in Table 4. Of interest, two samples demonstrated two
mutations: a primary KIT exon 11 mutation with KIT sec-
ondary exon 17 mutation, which included the patient with
prolonged stable disease. A correlation between type of
mutation and clinical outcome is shown in Table 4.
Discussion
The use of tyrosine kinase inhibitors has revolutionized the
management of GIST, signiWcantly improving patient out-
comes. At present, patients progressing on Wrst-line
imatinib treatment have the possibility of imatinib dose
Table 1 Patient demographics (n =1 3 )
Age in years
Median 63
Range 54–78
n (%)
Sex
Male 9 (69.2)
Female 4 (30.8)
Race
White 10 (77)
Black 3 (23)
ECOG performance status
0 4 (30.8)
1 9 (69.2)
20
Primary site of tumor
Stomach 6 (46.1)
Small bowel 5 (38.5)
Colon 1 (7.7)
Rectum 1 (7.7)
Metastatic sites
Liver 11 (84.6)
Peritoneum/abdomen 7 (53.8)
Pelvis 4 (30.8)
Lung 2 (15.4)
Spleen 1 (7.7)
Bone 1 (7.7)
Lymph node 1 (7.7)980 Cancer Chemother Pharmacol (2012) 69:977–982
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escalation or treatment with sunitinib. However, despite
initial response or stabilization, secondary resistance devel-
ops in most of the patients. The acquired resistance to
imatinib and sunitinib represents a major clinical challenge,
and this phase II study tested the beneWt of nilotinib in
patients, that had failed treatment with at least imatinib and
sunitinib, and the correlation between clinical outcome and
mutational status of the tumor.
Nilotinib administered as a single agent was well toler-
ated, conWrming other reports in GIST patients. Accrual of
patients was halted due to insuYcient clinical beneWt. No
patient had a complete or a partial response, and a stable
disease was observed in 30% of patients. It should be
noted that objective responses in GIST patients that have
Table 3 Best tumor response as determined by RECIST and by CHOI
criteria, n =1 3
a CHOI responses were assessable in 8 patients only, due to the use of
MRI or CT without IV contrast imaging in 4 patients, and one patient
was inevaluable due to lack of follow-up imaging
b CHOI PR was SD by RECIST. The CHOI SD were evaluated as SD
and PD by RECIST
Response RECIST/n (%) CHOIa/n (%)
CR 0 0
PR 0 1b (8)
SD 4 (31) 2b (15)
PD 8 (62) 5 (38)
NE 1 (8) 5 (38)
Table 2 Toxicities attributable 
to nilotinib
Adverse event (n = 13) Grade (NCI—CTCAE version 3.0), n (%)
1 2 3 4 All grades
Anemia 6 (46) 5 (38.5) 0 1 (7.7) 12 (92)
Leukopenia 6 (46) 1 (7.7) 0 0 7 (54)
Neutropenia 3 (23) 0 0 0 3 (23)
Thrombocytopenia 0 0 0 0 0
Fatigue 12 (92) 1 (7.7) 0 0 13 (100)
Diarrhea 5 (38.5) 0 0 0 5 (38.5%)
Constipation 4 (30.8) 2 (15) 1 (7.7) 0 7 (54)
Rash 5 (38.5) 0 0 0 5 (38.5)
Pruritus 1 (7.7) 0 0 0 1 (7.7)
Edema 1 (7.7) 2 (15) 0 0 3 (23)
Nausea 5 (38.5) 0 0 0 5 (38.5)
Vomiting 2 (15) 0 0 0 2 (15)
Anorexia 8 (61) 0 0 0 8 (61)
Abdominal pain 4 (30.8) 0 1 (7.7) 0 5 (38.5)
Headache 0 0 0 0 0
Bone pain 0 1 (7.7) 0 0 1 (7.7)
Voice change 4 (30.8) 0 0 0 4 (30.8)
Dyspnea 4 (30.8) 1 (7.7) 0 0 5 (38.5)
Cough 2 (15) 0 0 0 2 (15)
Arthralgia/myalgia 4 (30.8) 0 0 0 4 (30.8%)
Infection 0 1 (7.7) 0 0 1 (7.7)
Elevated creatinine 3 (23) 1 (7.7) 0 0 4 (30.8)
Transaminitis 3 (23) 1 (7.7) 0 0 4 (30.8)
Elevated bilirubin 2 (15) 0 0 0 2 (15)
Elevated alkaline phosphatase 4 (30.8) 1 (7.7) 1 (7.7) 0 6 (46)
Elevated amylase/lipase 2 (15) 0 0 0 2 (15)
Hypoalbuminemia 4 (30.8) 2 (15) 0 0 6 (46)
Hyponatremia 4 (30.8) 0 0 0 4 (30.8)
Hyperkalemia 5 (38.5) 0 0 0 5 (38.5)
Hypocalcemia 1 (7.7) 0 0 0 1 (7.7)
Hypomagnesemia 4 (30.8) 0 0 0 4 (30.8)Cancer Chemother Pharmacol (2012) 69:977–982 981
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progressed on standard therapies are uncommon, and thus
the lack of CR or PR is not surprising. Median progression-
free survival was 2 months.
In contrast to other reports of the beneWt of nilotinib in
patients with advanced GIST, the progression-free survival
in our study was shorter than that reported elsewhere. A ret-
rospective European analysis of 52 patients treated with nil-
otinib showed objective response in 10% of patients (95%
CI 2–18); 37% (95% CI 24–50) had disease stabilization.
Median PFS and OS were 12 weeks (95% CI 9–15) and
34 weeks (95% CI 3–65), respectively [8]. In a phase II
Japanese study, 35 patients were treated with nilotinib.
Median PFS was 113 days and median OS was 310 days;
disease control rate at 24 weeks was 28.6% (90% CI 16.4–
43.6%); 65.7% of patients had a stable disease, and 2.9%
had a partial response [9]. In a Korean study, 2 of 17
patients, treated with nilotinib, had a partial response and
10 of 17 had a stable disease with a clinical beneWt rate at
24 weeks of 47%. Median PFS and OS were 23.6 weeks
(95% CI 0–50.6 weeks) and 74 weeks (95% CI 27.4–
120.6 weeks), respectively [10]; intriguingly this study
evaluated drug levels and noted lower serum levels of nil-
otinib in patients with gastric resections, particularly those
with complete resections. In our study, one patient had had
a prior total gastrectomy (PD after 1 cycle) and an addi-
tional 3 patients had partial or hemigastrectomies (PD after
2–3 cycles). Lastly, the phase III trial of Nilotinib com-
pared with supportive care, including the use of imatinib or
sunitinib, did not demonstrate a signiWcant progression-free
or overall survival beneWt in a similar study population;
there did appear, however, to be a progression beneWt in
those patients who entered on the study after therapy only
with imatinib and sunitinib [11]. Our statistical assump-
tions lead to early termination of our accrual and thus may
have limited our power to detect a beneWt of nilotinib.
The correlation between clinical outcome and tumor
genotype is of interest. Secondary mutations in exons 13 and
14 are known to be well controlled by sunitinib; however,
those in exon 17 are not [12]. The patient that remained on
study for 12 cycles had a biopsy prior to study entry that
demonstrated a primary KIT exon 11 (alteration beginning
at K558) with a secondary exon 17 mutation (Y823D).
In vitro studies by Guo and colleagues suggested that Niloti-
nib in cell lines transfected with a KIT gene containing an
exon 9 or 11 mutation with an exon 17 mutation (D820Y
and N822 K) demonstrated signiWcant kinase inhibition as
well as decreased cell proliferation The Japanese study also
documented a partial response in patients whose GIST con-
tained a KIT exon 11 (dup 567–576) and exon 17 (D820G)
mutation [9]. The beneWt of nilotinib for patients with exon
11 and 17 mutations is intriguing but appears to be depen-
dent on the speciWc secondary mutation in exon 17. In addi-
tion, other cellular factors beyond the mutations may play a
role in whether a response is noted, as is exempliWed by our
second patient with the exon 11 (alteration beginning at 558)
and exon 17 (N822 K), who would have been predicted to
have beneWt from nilotinib based on in vitro data, but whose
tumor progressed after 2 months of therapy.
We concluded that nilotinib was generally well tolerated
and may provide beneWt to speciWc subset of advanced
GIST with secondary KIT exon 17 mutations, a group of
patients that have no standard therapeutic options. Further
studies are needed to conWrm these data and to deWne the
role of nilotinib for treatment of GIST, alone or in combi-
nation with other drugs.
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Table 4 Correlation 
of mutation with clinical 
outcome on nilotinib
Type of mutation Clinical outcome
KIT exon 11—1691del6 at amino acid 556 PD after 3 cycles
KIT exon 11—alteration begins at K550 SD after 2 cycles
KIT exon 11—alteration begins at Q556 PD post 2 cycles
KIT exon 11—V599D PD after 3 cycles
KIT exon 11—L576P SD post 2 cycles
KIT exon 11—alteration begins at K558 and KIT exon 17—N822 K PD post 2 cycles
KIT exon 11—alteration begins at V555 and KIT exon 17—Y823D PD after 12 cycles
KIT exon 9 mutation—A502_Y503del PD post 2 cycles
No identiWable mutation in KIT or PDGFRA PD post 2 cycles
No identiWable mutation in KIT or PDGFRA PD post 2 cycles
PD progressive disease; 
SD stable disease982 Cancer Chemother Pharmacol (2012) 69:977–982
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